• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

    14.79 -0.77 (-4.95%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Adaptive Biotechnologies Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
    clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session
     
    Via Benzinga
    Earnings Scheduled For May 1, 2025
     
    Via Benzinga
    Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
    On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China. 
    Via Benzinga
    Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Analyst Expectations For Adaptive Biotechnologies's Future
     
    Via Benzinga
    Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
    Small caps took another step down this past week as geopolitical events dampened sentiment. 
    Via Talk Markets
    Topics ETFs Stocks / Equities
    Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
     
    Via Benzinga
    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Earnings Scheduled For February 11, 2025
     
    Via Benzinga
    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
    The company expects sales to grow 12% to 13% annually in the long term. 
    Via Investor's Business Daily
    Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
    Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
    Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
    Via Benzinga
    Topics Artificial Intelligence
    Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
    Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
    Via Benzinga
    Topics Workforce
    Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks
    The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
    Via Talk Markets
    Topics ETFs Stocks / Equities
    Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Top 3 Health Care Stocks That May Collapse This Quarter
     
    Via Benzinga
    Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
    From Adaptive Biotechnologies
    Via GlobeNewswire
    Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
    Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
    Via Benzinga
    Topics Artificial Intelligence
    Smaller Cap Biotechs Are In Season: How Are We Doing?
    SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.